Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | GGPS1 | O95749 | 6/20 | 0.37 |
| ▸ | EBP | Q15125 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | FDPS | P14324 | 9/20 | 0.35 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.34 |
| ▸ | CES2 | O00748 | 1/20 | 0.34 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.34 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28191748 | 1.00 | TSHR (0.40) | TSHRTHRBGGPS1EBPSIGMAR1 | |
| SCHEMBL12208739 | 1.00 | TSHR (0.40) | TSHRTHRBGGPS1EBPSIGMAR1 | |
| SCHEMBL9912385 | 1.00 | TSHR (0.40) | TSHRTHRBGGPS1EBPSIGMAR1 | |
| SCHEMBL10029661 | 1.00 | TSHR (0.40) | TSHRTHRBGGPS1EBPSIGMAR1 | |
| SCHEMBL28930082 | 1.00 | TSHR (0.40) | TSHRTHRBGGPS1EBPSIGMAR1 | |
| SCHEMBL12808432 | 0.98 | TSHR (0.38) | TSHRTHRBGGPS1EBPSIGMAR1 | |
| Phosphine SCHEMBL11050682 | 0.98 | TSHR (0.38) | TSHRTHRBGGPS1EBPSIGMAR1 | |
| SCHEMBL366645 | 0.97 | TSHR (0.38) | TSHRTHRBGGPS1EBPSIGMAR1 | |
| SCHEMBL23508852 | 0.95 | TSHR (0.36) | TSHRTHRBGGPS1EBPSIGMAR1 | |
| SCHEMBL10029774 | 0.95 | TSHR (0.36) | TSHRTHRBGGPS1EBPSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11139436-B2 | Organic compound, and light-emitting diode and light-emitting device including the same | LG DISPLAY CO., LTD. (KR) | 2021-10-05 | — | — | US | disclosed |
| US-10577362-B2 | Substituted 2, 4-diamino-quinoline derivatives for use in the treatment of proliferative diseases | GENOSCIENCE PHARMA (FR) | 2020-03-03 | — | — | US | disclosed |
| US-20190144437-A1 | SUBSTITUTED 2, 4-DIAMINO-QUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | GENOSCIENCE PHARMA (FR) | 2019-05-16 | — | — | US | disclosed |
| US-20190131548-A1 | ORGANIC COMPOUND, AND LIGHT-EMITTING DIODE AND LIGHT-EMITTING DEVICE INCLUDING THE SAME | LG DISPLAY CO., LTD. (KR) | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190131548-A1 | ORGANIC COMPOUND, AND LIGHT-EMITTING DIODE AND LIGHT-EMITTING DEVICE INCLUDING THE SAME | DRD1, DRD2, ALDH1A2 | TSHR 1352/4885THRB 835/4885GGPS1 2432/4885 |
| US-11139436-B2 | Organic compound, and light-emitting diode and light-emitting device including the same | DRD1, DRD2, ALDH1A2 | TSHR 1352/4885THRB 835/4885GGPS1 2432/4885 |
| US-20190144437-A1 | SUBSTITUTED 2, 4-DIAMINO-QUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | NQO2, RECQL, CCNO | TSHR 3904/4885THRB 4176/4885GGPS1 1832/4885 |
| US-10577362-B2 | Substituted 2, 4-diamino-quinoline derivatives for use in the treatment of proliferative diseases | NQO2, RECQL, CCNO | TSHR 3904/4885THRB 4176/4885GGPS1 1832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.